ANKRD50

Summary

ANKRD50 (ankyrin repeat domain 50, HGNC:29223) is a protein-coding gene on chromosome 4q28.1, encoding Ankyrin repeat domain-containing protein 50 (Q9ULJ7). Involved in the endosome-to-plasma membrane trafficking and recycling of SNX27-retromer-dependent cargo proteins, such as GLUT1.

Involved in endocytic recycling. Predicted to be located in endosome.

Source: NCBI Gene 57182 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 9
• Clinical variants (ClinVar): 186 total — 2 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_020337

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29223
Approved symbol	ANKRD50
Name	ankyrin repeat domain 50
Location	4q28.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1223
Ensembl gene	ENSG00000151458
Ensembl biotype	protein_coding
OMIM	619856
Entrez	57182

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000504087, ENST00000515641, ENST00000871953

RefSeq mRNA: 2 — MANE Select: NM_020337 NM_001167882, NM_020337

CCDS: CCDS34060, CCDS54802

Canonical transcript exons

ENST00000504087 — 5 exons

Exon	Start	End
ENSE00000999699	124668984	124672534
ENSE00002026096	124664048	124667514
ENSE00002032218	124710000	124711274
ENSE00002039313	124712458	124712732
ENSE00003611455	124678676	124678905

Expression profiles

Bgee: expression breadth ubiquitous, 246 present calls, max score 98.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.8054 / max 278.1557, expressed in 1738 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
53865	15.1459	1737
53864	0.6595	374

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	98.02	gold quality
skin of hip	UBERON:0001554	95.44	gold quality
upper leg skin	UBERON:0004262	95.07	gold quality
visceral pleura	UBERON:0002401	94.76	gold quality
cauda epididymis	UBERON:0004360	94.08	gold quality
upper arm skin	UBERON:0004263	93.93	gold quality
epithelial cell of pancreas	CL:0000083	93.16	gold quality
endothelial cell	CL:0000115	93.11	gold quality
parietal pleura	UBERON:0002400	91.47	gold quality
cortical plate	UBERON:0005343	90.95	gold quality
esophagus squamous epithelium	UBERON:0006920	90.75	gold quality
tibia	UBERON:0000979	90.64	gold quality
calcaneal tendon	UBERON:0003701	90.52	gold quality
germinal epithelium of ovary	UBERON:0001304	89.96	gold quality
stromal cell of endometrium	CL:0002255	89.06	gold quality
cardiac muscle of right atrium	UBERON:0003379	89.05	silver quality
seminal vesicle	UBERON:0000998	88.88	gold quality
ganglionic eminence	UBERON:0004023	88.76	gold quality
gingival epithelium	UBERON:0001949	88.64	gold quality
gingiva	UBERON:0001828	88.15	gold quality
tendon	UBERON:0000043	87.29	gold quality
trabecular bone tissue	UBERON:0002483	87.12	gold quality
placenta	UBERON:0001987	86.53	gold quality
mucosa of paranasal sinus	UBERON:0005030	86.20	gold quality
urinary bladder	UBERON:0001255	85.63	gold quality
lower lobe of lung	UBERON:0008949	85.49	gold quality
saphenous vein	UBERON:0007318	85.25	gold quality
palpebral conjunctiva	UBERON:0001812	85.11	gold quality
ventricular zone	UBERON:0003053	85.11	gold quality
tendon of biceps brachii	UBERON:0008188	84.87	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.81
E-MTAB-6058	no	63.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

245 targeting ANKRD50, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-8485	100.00	77.57	4731
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-4262	100.00	73.26	3931
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-570-3P	99.96	72.41	4910

Literature-anchored findings (GeneRIF, showing 1)

• ANKRD50 simultaneously engages multiple parts of the SNX27-retromer-WASH complex machinery in a direct and co-operative interaction network that is needed to efficiently recycle the nutrient transporters. (PMID:27909246)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ANKRD50	ENSDARG00000045666
danio_rerio	ankrd50	ENSDARG00000079065
mus_musculus	Ankrd50	ENSMUSG00000044864
rattus_norvegicus	Ankrd50	ENSRNOG00000010534
drosophila_melanogaster	CG10011	FBGN0039590
caenorhabditis_elegans		WBGENE00012124

Protein

Protein identifiers

Ankyrin repeat domain-containing protein 50 — Q9ULJ7 (reviewed: Q9ULJ7)

All UniProt accessions (1): Q9ULJ7

UniProt curated annotations — full annotation on UniProt →

Function. Involved in the endosome-to-plasma membrane trafficking and recycling of SNX27-retromer-dependent cargo proteins, such as GLUT1.

Subunit / interactions. Interacts with VPS35.

Subcellular location. Endosome.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9ULJ7-1	1	yes
Q9ULJ7-2	2

RefSeq proteins (2): NP_001161354, NP_065070* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR056884	NPHP3-like_N	Domain
IPR058018	AAA_lid_TANC1/2	Domain
IPR058056	WH_TANC1/2	Domain

Pfam: PF00023, PF12796, PF24883, PF25520, PF25521

UniProt features (39 total): repeat 19, sequence conflict 7, compositionally biased region 5, modified residue 4, region of interest 2, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULJ7-F1	74.26	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 1165, 1167, 1222, 1400

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 171 (showing top): GCACCTT_MIR18A_MIR18B, TGCACTT_MIR519C_MIR519B_MIR519A, GOZGIT_ESR1_TARGETS_DN, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, GCM_PPM1D, GOBP_VESICLE_MEDIATED_TRANSPORT, ACTGCAG_MIR173P, GOBP_ENDOCYTIC_RECYCLING, BASAKI_YBX1_TARGETS_DN, YAMAZAKI_TCEB3_TARGETS_UP, GOBP_LOCALIZATION_WITHIN_MEMBRANE, ATGTTTC_MIR494, ATGTACA_MIR493, GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D, MODULE_139

GO Biological Process (2): protein transport (GO:0015031), endocytic recycling (GO:0032456)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): endosome (GO:0005768)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	1
intracellular protein localization	1
establishment of protein localization	1
endosomal transport	1
vesicle-mediated transport to the plasma membrane	1
binding	1
endomembrane system	1
cytoplasmic vesicle	1

Protein interactions and networks

STRING

1458 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANKRD50	SNX27	Q96L92	738
ANKRD50	VPS29	Q9UBQ0	715
ANKRD50	ENTR1	Q96C92	570
ANKRD50	VPS35	Q96QK1	528
ANKRD50	WDR25	Q64LD2	524
ANKRD50	FAM8A1	Q9UBU6	479
ANKRD50	VPS26A	O75436	470
ANKRD50	ANKRD27	Q96NW4	470
ANKRD50	TPRA1	Q86W33	462
ANKRD50	DNAJC13	O75165	460
ANKRD50	PDHA2	P29803	457
ANKRD50	WASHC5	Q12768	455
ANKRD50	VPS26B	Q4G0F5	453
ANKRD50	SNX1	Q13596	452
ANKRD50	SLC5A9	Q2M3M2	451

IntAct

45 interactions, top by confidence:

A	B	Type	Score
VPS29	VPS26C	psi-mi:“MI:0914”(association)	0.760
ODAPH	TCAF2	psi-mi:“MI:0914”(association)	0.530
ARL13B	STK25	psi-mi:“MI:0914”(association)	0.530
DDX41	NOS1AP	psi-mi:“MI:0914”(association)	0.530
VPS35	ANKRD50	psi-mi:“MI:0914”(association)	0.530
EMILIN3	ZZEF1	psi-mi:“MI:0914”(association)	0.530
ANKRD50		psi-mi:“MI:0915”(physical association)	0.490
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
ANKRD50	SCRIB	psi-mi:“MI:0915”(physical association)	0.400
ANKRD50	MLF2	psi-mi:“MI:0915”(physical association)	0.400
CLNK	ANKRD50	psi-mi:“MI:0915”(physical association)	0.370
ANKRD50		psi-mi:“MI:0915”(physical association)	0.370
	ANKRD50	psi-mi:“MI:0915”(physical association)	0.370
GAMMAHV.ORF40	ANKRD50	psi-mi:“MI:0915”(physical association)	0.370
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
HIF1AN	CNOT1	psi-mi:“MI:0914”(association)	0.350
ZNF414	ANKHD1	psi-mi:“MI:0914”(association)	0.350
VPS35	WASHC1	psi-mi:“MI:0914”(association)	0.350
VPS35	ILVBL	psi-mi:“MI:0914”(association)	0.350
C12orf57	TANC1	psi-mi:“MI:0914”(association)	0.350
CAPZB	ENAH	psi-mi:“MI:0914”(association)	0.350

BioGRID (127): ANKRD50 (Two-hybrid), ANKRD50 (Affinity Capture-MS), ANKRD50 (Two-hybrid), ANKRD50 (Affinity Capture-MS), ANKRD50 (Biochemical Activity), ANKRD50 (Affinity Capture-MS), ANKRD50 (Affinity Capture-MS), ANKRD50 (Affinity Capture-MS), ANKRD50 (Affinity Capture-MS), ANKRD50 (Affinity Capture-MS), ANKRD50 (Affinity Capture-MS), ANKRD50 (Affinity Capture-MS), PEX5 (Two-hybrid), ANKRD50 (Affinity Capture-RNA), ANKRD50 (Proximity Label-MS)

ESM2 similar proteins: A2AS55, B2RXR6, O15084, O75832, P0C927, Q08DV6, Q0P5B9, Q29RM5, Q2TB02, Q3SX45, Q495B1, Q499M5, Q4V890, Q502K3, Q505D1, Q53RE8, Q5F478, Q5RFS1, Q5U2S6, Q5ZLC8, Q6GPE5, Q6P6B7, Q6P9Z4, Q70X92, Q7T3P8, Q810B6, Q8BTI7, Q8C0T1, Q8C6Y6, Q8K0L0, Q8N8A2, Q8NB46, Q8NI38, Q8WXH4, Q91ZT8, Q96AX9, Q96DX5, Q96NS5, Q96Q27, Q9BSK4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 48 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by Rho GTPases	5	6.3×	3e-03
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	5	6.2×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

186 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	1
Uncertain significance	167
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
1047888	GRCh37/hg19 4q26-28.2(chr4:116833638-130232122)	Pathogenic
59480	GRCh38/hg38 4q28.1(chr4:124055204-126331108)x1	Pathogenic
226172	GRCh37/hg19 4q28.1(chr4:125251081-128286629)	Likely pathogenic

SpliceAI

937 predictions. Top by Δscore:

Variant	Effect	Δscore
4:124672531:AAAC:A	acceptor_gain	1.0000
4:124672532:AAC:A	acceptor_gain	1.0000
4:124672533:AC:A	acceptor_gain	1.0000
4:124672534:CC:C	acceptor_gain	1.0000
4:124672535:C:CC	acceptor_gain	1.0000
4:124672535:C:CG	acceptor_loss	1.0000
4:124678702:CT:C	donor_gain	1.0000
4:124678901:CACAC:C	acceptor_gain	1.0000
4:124678903:CAC:C	acceptor_gain	1.0000
4:124672530:AAAAC:A	acceptor_gain	0.9900
4:124672535:C:T	acceptor_gain	0.9900
4:124678701:A:AC	donor_gain	0.9900
4:124678702:C:CC	donor_gain	0.9900
4:124678702:CTCTG:C	donor_gain	0.9900
4:124678904:ACCT:A	acceptor_loss	0.9900
4:124678905:CCT:C	acceptor_loss	0.9900
4:124678906:CTGTA:C	acceptor_loss	0.9900
4:124678907:T:C	acceptor_loss	0.9900
4:124672546:A:AC	acceptor_gain	0.9800
4:124672546:A:C	acceptor_gain	0.9800
4:124678902:ACAC:A	acceptor_gain	0.9800
4:124678903:CACC:C	acceptor_gain	0.9800
4:124678904:AC:A	acceptor_gain	0.9800
4:124678905:CC:C	acceptor_gain	0.9800
4:124678906:C:CC	acceptor_gain	0.9800
4:124695061:T:C	donor_gain	0.9800
4:124711275:C:CC	acceptor_gain	0.9800
4:124665416:T:C	acceptor_gain	0.9700
4:124665416:T:TC	acceptor_gain	0.9700
4:124667515:C:CC	acceptor_gain	0.9700

AlphaMissense

9325 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:124670214:C:A	W1021C	1.000
4:124670214:C:G	W1021C	1.000
4:124670216:A:G	W1021R	1.000
4:124670216:A:T	W1021R	1.000
4:124670776:A:G	L834P	1.000
4:124670779:A:G	L833P	1.000
4:124670779:A:T	L833Q	1.000
4:124670815:G:T	A821D	1.000
4:124670824:A:G	L818P	1.000
4:124670824:A:T	L818H	1.000
4:124670832:C:A	R815S	1.000
4:124670832:C:G	R815S	1.000
4:124670833:C:G	R815T	1.000
4:124671257:C:G	D674H	1.000
4:124671318:C:A	W653C	1.000
4:124671318:C:G	W653C	1.000
4:124671320:A:G	W653R	1.000
4:124671320:A:T	W653R	1.000
4:124672014:A:C	C421W	1.000
4:124672035:C:A	W414C	1.000
4:124672035:C:G	W414C	1.000
4:124672037:A:G	W414R	1.000
4:124672037:A:T	W414R	1.000
4:124672271:A:G	W336R	1.000
4:124672271:A:T	W336R	1.000
4:124672273:A:G	L335P	1.000
4:124672282:C:T	G332D	1.000
4:124672283:C:G	G332R	1.000
4:124672297:G:T	P327Q	1.000
4:124672360:A:G	L306P	1.000

dbSNP variants (sampled 300 via entrez): RS1000014384 (4:124670084 A>G), RS1000023261 (4:124663834 T>C), RS1000076289 (4:124687252 GTTTTTTGT>G), RS1000094034 (4:124671217 A>G), RS1000169414 (4:124666359 C>T), RS1000224101 (4:124712231 C>T), RS1000225622 (4:124685064 C>T), RS1000230790 (4:124702725 T>G), RS1000254619 (4:124709870 T>C), RS1000278366 (4:124712403 C>G), RS1000359926 (4:124673917 AATTG>A), RS1000393398 (4:124696555 C>T), RS1000409584 (4:124703047 C>G,T), RS1000477835 (4:124709517 A>G), RS1000575148 (4:124690100 A>G)

Disease associations

OMIM: gene MIM:619856 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST003072_2	Cerebrospinal fluid AB1-42 levels	6.000000e-07
GCST004865_78	Itch intensity from mosquito bite adjusted by bite size	6.000000e-07
GCST005057_4	Small vessel stroke	8.000000e-06
GCST008646_5	Gastric cancer	3.000000e-11
GCST009391_1256	Metabolite levels	3.000000e-06
GCST009391_206	Metabolite levels	2.000000e-07
GCST009391_212	Metabolite levels	4.000000e-06
GCST011742_15	Triglyceride levels in HIV infection	5.000000e-06
GCST011742_2	Triglyceride levels in HIV infection	5.000000e-06

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004670	beta-amyloid 1-42 measurement
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:1001504	small vessel stroke
EFO:0004761	uric acid measurement
EFO:0004530	triglyceride measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	6
Nickel	decreases expression	3
trichostatin A	affects cotreatment, decreases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	affects phosphorylation	1
methylmercuric chloride	decreases expression	1
bisphenol A	decreases methylation	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
potassium chromate(VI)	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
(+)-JQ1 compound	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Leflunomide	increases expression	1
Acetaminophen	increases expression	1
Air Pollutants, Occupational	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Caffeine	decreases phosphorylation	1
Cisplatin	affects cotreatment, decreases expression	1
Curcumin	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety